Compare Revvity Inc (RVTY) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs BlackRock TCP Capital Corp — how do they compare? Revvity Inc trades at $124.14 (market cap $14.18B), while BlackRock TCP Capital Corp trades at $4.03 (market cap $341.90M). The key difference: Revvity Inc is far larger — about 41.5× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (18.65%). Which is the better fit depends on your goals.
| RVTY | TCPC | |
|---|---|---|
Market Cap | $14.18B | $341.90M |
Sector | Technology | Financials |
52-Week High | $130.94 | $7.22 |
52-Week Low | $82.26 | $3.13 |
Enterprise Value | $16.50B | — |
Dividend Yield | 0.22% | 18.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.
Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.
TCPC trades at $4.07, showing no daily change. The stock exhibits bearish technical signals with flat support/resistance at $4. Recent earnings showed mixed results with Q2 2026 beating estimates at $0.22 EPS versus $0.20 expected. The company faces fundamental challenges with negative revenue of -$77.27M and net income of -$88.93M for 2025, though it maintains a dividend payout of $0.17 quarterly.
Investment outlook remains cautious due to negative profitability metrics and ongoing strategic review. The company's portfolio sale and leverage reduction provide some stability, but persistent revenue declines and class action lawsuits present significant risks. Analyst consensus leans neutral with 61.5% hold ratings, reflecting uncertainty about the company's turnaround prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
